Change in lymphocyte counts, CD4 and CD8 T-cell counts, and activated CD8 T cells after 1 cycle of mosunetuzumab. All comparisons depict counts at baseline (C1D1) and after 1 cycle of mosunetuzumab (C2D1) for patients with responding and nonresponding lymphoma. Circles indicate a patient with large B-cell lymphoma, and square boxes indicate a patient with follicular lymphoma. Blue indicates patients with response (CR/PR), and red indicates patients with no response (SD/PD). (A) Absolute lymphocyte count (ALC). ∗P = .02, for C2D1 comparison. (B) CD4 counts. (C) CD8 counts. (D) Difference in CD4 counts. ∗∗P = .005. (E) Difference in CD8 counts. ∗∗P = .004. (F) Fold change in activated CD8 T cells (CD8⁺CD25^–CD9⁺). ∗P = .02. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.